The Hindu Business Line Pfizer (Rs 632.90): Buy We recommend a buy in Pfizer from a short-term perspective. From the chart, we see that it had been on a medium-term downtrend from December 2007 high of Rs 850 to mid-February low of Rs 587. However, the stock’s medium-term downtrend got ... More The Economic Times Stocks to pick: SBI, Infosys Technologies, Crompton Greaves, GLaxosmithkline State Bank of India Research: HSBC Rating: Underweight CMP: Rs 2,115 Infosys Technologies Research: Indiabulls Financials Rating: Buy CMP: Rs 1,580 Crompton Greaves Research: JM Financials Rating: Buy CMP: Rs 298 GLaxosmithkline Pharma Research: Motilal Oswal Rating: Buy CMP: Rs 953
This is my investment scrapbook. My request to viewers would be to use their own judgment before taking call on any shares mentioned here. Moreover, although I always try to be accurate and correct , there is no guarantee of the accuracy and correctness of the information provided here. Viewers would be using information provided here at their own risk. I won't be liable for any loss whatsoever for transaction based on the information provided here.